A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Trial Profile

A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs VS 5584 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Verastem
  • Most Recent Events

    • 23 Dec 2016 Status changed from recruiting to discontinued.
    • 09 May 2016 According to a Verastem media release, the maximum tolerated dose has been reached and the recommended phase II dose is being confirmed in this trial.
    • 28 Oct 2015 Planned number of patients changed from 62 to 100 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top